scholarly journals Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: Lessons learned from acetaminophen hepatotoxicity

2012 ◽  
Vol 44 (1) ◽  
pp. 88-106 ◽  
Author(s):  
Hartmut Jaeschke ◽  
Mitchell R. McGill ◽  
Anup Ramachandran
Cytokine ◽  
2016 ◽  
Vol 86 ◽  
pp. 21-28 ◽  
Author(s):  
Keisuke Kakisaka ◽  
Kojiro Kataoka ◽  
Yuji Suzuki ◽  
Yohei Okada ◽  
Yuichi Yoshida ◽  
...  

2018 ◽  
Vol 132 (5) ◽  
pp. 609-613 ◽  
Author(s):  
Salvatore Sutti ◽  
Frank Tacke

Drug-induced liver injury (DILI) remains a clinical challenge due to the poorly predictable outcomes. Accordingly, considerable efforts have been devoted to unravel the risk factors responsible for DILI worsening toward acute liver failure (ALF), liver transplantation (LT), and/or death. From a pathogenic point of view, exhaustion of drug metabolizing pathways, cell death mechanisms, activation of local immune cells, such as Kupffer cells, and recruitment of inflammatory leukocytes including monocytes and lymphocytes are key drivers of DILI progression. Taking into account that the liver is a sexually dimorphic organ, in the recent past several studies aimed to investigate the implications of gender differences in promoting DILI. While sex discrepancies in DILI include the hepatic drug metabolism or direct effects of steroid hormones (e.g. androgens and estrogens) on signaling pathways in the liver, relatively little is known on gender differences in modulating liver innate immune responses. In a previous issue of Clinical Science, Bizzaro and co-workers, analyzed sex-dependent differences in experimental acute liver injury and regeneration in mice. The authors observed a time-delay in the recovery process in male animals associated with a higher recruitment of monocytes expressing the androgen receptor (AR) as compared with females. Treatment of male mice with the pharmacological AR antagonist flutamide reduced monocyte recruitment in mice. Likewise, human male patients suffering from DILI displayed higher circulating immature and potentially more inflammatory monocytes. Altogether, these observations provide new insights into sex-dependent immune mechanisms in the context of acute liver injury, suggesting gender disparate inflammatory and regenerative responses following DILI.


2021 ◽  
pp. 096032712110279
Author(s):  
BY Ghanim ◽  
MI Ahmad ◽  
QM Abdallah ◽  
LA Qatouseh ◽  
NA Qinna

Transcriptional factor NRF2 is an emerging tool in reviewing mechanistic behavior of drug-specific injury pathways. Drug-induced liver injury (DILI) represents a major clinical concern that often manifests oxidative stress and cell death. Despite the pivotal role of NRF2 pathway in liver pathologies, it is questioned whether NRF2 activation or regulatory efficiency could be hindered in by the severity of DILI and progression of cell death. In this study, we evaluate NRF2 as a biomarker to DILI in comparison to severity of injury as well as explore stress mediating factors affecting Nrf2 expression. In vivo DILI model was established in C57BL/6 mice by acetaminophen (APAP) at different toxic doses, confirmed by dose-dependent liver pathological changes and accompanied with in vitro time- and dose-dependent depletion of GSH and SOD in isolated primary mouse hepatocytes. Increase in liver NRF2 translocation and cytosolic content was observed in 70 mg/kg APAP-treated mice. At this subtoxic dose, liver Nrf2 transcription was increased in mice by 18.3-fold, a prominent downregulation was seen in ARE (antioxidant response element) genes; Hmox1, Nqo1 and Glcm, and apoptotic Bcl2 regulating genes. In addition, upregulation in necrosis inducer Parp2 was associated to downregulation in Hmgb1. Collectively, expression of genes related to cell survival were regulated at mild APAP hepatotoxicity. By increasing APAP dose, hemorrhagic necrosis and impaired genetic transcription in both Nrf2 and several other genes were evident. In conclusion, NRF2/ARE system and cell death modulation is halted by the increase of chemical stress and found directly associated with DILI severity.


2015 ◽  
Vol 33 (4) ◽  
pp. 464-471 ◽  
Author(s):  
Hartmut Jaeschke

Background: Drug-induced liver injury is a rare but serious clinical problem. A number of drugs can cause severe liver injury and acute liver failure at therapeutic doses in a very limited number of patients (<1:10,000). This idiosyncratic drug-induced liver injury, which is currently not predictable in preclinical safety studies, appears to depend on individual susceptibility and the inability to adapt to the cellular stress caused by a particular drug. In striking contrast to idiosyncratic drug-induced liver injury, drugs with dose-dependent hepatotoxicity are mostly detected during preclinical studies and do not reach the market. One notable exception is acetaminophen (APAP, paracetamol), which is a safe drug at therapeutic doses but can cause severe liver injury and acute liver failure after intentional and unintentional overdoses. Key Messages: APAP overdose is responsible for more acute liver failure cases in the USA or UK than all other etiologies combined. Since APAP overdose in the mouse represents a model for the human pathophysiology, substantial progress has been made during the last decade in understanding the mechanisms of cell death, liver injury and recovery. More recently, emerging evidence based on mechanistic biomarker analysis in patients and studies of cell death in human hepatocytes suggests that most of the mechanisms discovered in mice also apply to patients. The rapid development of N-acetylcysteine as an antidote against APAP overdose was based on the early understanding of APAP toxicity in mice. However, despite the efficacy of N-acetylcysteine in patients who present early after APAP overdose, there is a need to develop intervention strategies for late-presenting patients. Conclusions: The challenges related to APAP toxicity are to better understand the mechanisms of cell death in order to limit liver injury and prevent acute liver failure, and also to develop biomarkers that better predict as early as possible who is at risk for developing acute liver failure with poor outcome.


Sign in / Sign up

Export Citation Format

Share Document